Genzyme CorporateResearchSearchGenzyme Websites
Patients and FamiliesHeath Care Professionals

Health Care Professionals
About Renvela
Events
Related Links

Related Links

American Nephrology Nurse’s Association

American Society of Nephrology

American Society of Transplantation

Centers for Medicare & Medicaid Services (CMS)

Food and Drug Administration

Forum of ESRD Networks

Genzyme Renal Innovations Program (GRIPresearch.org)

Hypertension, Dialysis and Clinical Nephrology

Information for Vermont Prescribers of Prescription Drugs (PDF)

Kidney and Urology Foundation

Kidney Transplant Dialysis Association

Life Options rehabilitation Program

National Institute of Diabetes and Digestive and Kidney Diseases

National Kidney Foundation

National Renal Administrators Association

National Transplant Assistance Fund

Nephrology Linx

Nephron Information Center

Physicians Weekly

Polycystic Kidney Foundation

Renal Net

Renal Physicians Association

Renal Web

Transweb

US Renal Data System


Genzyme Renvela

Important Treatment Considerations

Renvela® (sevelamer carbonate) is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis

  • Renvela is contraindicated in patients with bowel obstruction
  • Caution should be exercised in patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders including severe constipation, or major GI tract surgery
  • Uncommon cases of bowel obstruction and perforation have been reported
  • Serum bicarbonate and chloride levels should be monitored
  • Vitamins D, E, K (coagulation parameters), and folic acid levels should be monitored
  • The most frequently occurring adverse reactions in a short-term study with sevelamer carbonate tablets were nausea and vomiting
  • In a short-term study of sevelamer carbonate powder dosed three times daily, adverse events were similar to those reported for sevelamer carbonate tablets
  • In long-term studies with sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, the most common adverse events included: vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, and constipation
  • Cases of fecal impaction and, less commonly, ileus, bowel obstruction, and bowel perforation have been reported
  • Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take Renvela
  • Patients should be informed to take Renvela with meals and to adhere to their prescribed diets.

Please see accompanying full Prescribing Information.

Renagel® (sevelamer hydrochloride) is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis

  • Renagel is contraindicated in patients with hypophosphatemia or bowel obstruction
  • Caution should be exercised in patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders including severe constipation or major GI tract surgery
  • Common adverse events reported with Renagel include vomiting, nausea, diarrhea, dyspepsia, abdominal pain, and constipation
  • Other events reported include pruritus, rash, fecal impaction, and intestinal obstruction
  • Drug-drug interactions may occur with some medications and should be taken into consideration when instructing patients how to take Renagel
  • Patients should be informed to take Renagel with meals and to adhere to their prescribed diets

Please see accompanying full Prescribing Information.


Genzyme Renvela

Learn how the Renassist team can help patients access Renvela.
Go to the Renassist Website >

Contact
Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142
T: 800 847 0069
F: 617 252 7600

Email Us
© 2010 Genzyme Corporation | Terms and Conditions of Use | Privacy Policy